The present application provides a class of novel compounds having USP1 inhibitory activity as shown in formula (II), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method for treating related diseases mediated by a USP1 target by means of the compounds of the present application.

##STR00001##

A novel polycyclic aromatic compound in which plural aromatic rings are linked via boron atoms, oxygen atoms and the like is provided, and therefore, the range of selection of the material for organic electroluminescent elements can be widened. Also, an excellent organic electroluminescent element is provided by using the novel polycyclic aromatic compound as a material for an organic electroluminescent element.

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. ##STR00001##

A compound of the following structure is provided:

##STR00001## ##STR00002##

A compound of the following structure is provided:

##STR00001##

The present application discloses a small molecule compound having a phosphorylated aromatic structure and application thereof. The compound and pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof provided in the present application or the pharmaceutical composition provided in the second aspect of the present invention, by targeting the TEAD palmitoyl pocket, effectively inhibits/blocks YAP-TEAD binding, inhibits/blocks the transcription function of YAP-TEAD, thereby preventing and/or treating diseases related to increased TEAD transcription levels and/or YAP phosphorylation disorders and/or Hippo signaling pathway disorders.

The invention relates to Organic light emitting diode comprising at least one emission layer, an electron injection layer and at least one cathode electrode, wherein: the electron injection layer comprises an organic phosphine compound, wherein the electron injection layer is free of a metal, metal salt, metal complex and metal organic compound; the cathode electrode comprises at least a first cathode electrode layer, wherein the first cathode electrode layer comprises a first zero-valent metal selected from the group comprising alkali metal, alkaline earth metal, rare earth metal and/or a group 3 transition metal; and the electron injection layer is arranged in direct contact to the first cathode electrode layer.

A light-emitting device includes a first electrode, a second electrode facing the first electrode, and an interlayer including an emission layer between the first electrode and the second electrode and an electron transport region between the emission layer and the second electrode. The electron transport region includes an electron transport layer and an electron injection layer between the electron transport layer and the second electrode. The electron transport layer includes a first material and a second material, the electron injection layer includes a third material and a fourth material, and an amount of the third material is in a range of about 50 parts by weight to about 99 parts by weight, based on a total of 100 parts by weight of the electron injection layer. The first material to the fourth material are respectively the same as described in the specification.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I): ##STR00001##
The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):

##STR00001##

The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.